Source: BioHarvest Sciences
  • BioHarvest Sciences (BHSC) has closed the second tranche of its private placement of convertible notes
  • The company expects the offering to close an additional tranche of up to $3 million by December 15, 2022
  • Under the second tranche, the company issued notes in the principal amount of $2,612,742.28
  • Vancouver-based BioHarvest Sciences Inc. (BHSC) is the developer and exclusive owner of proprietary and patent-protected BioFarming technology
  • BioHarvest Sciences Inc. (BHSC) is up 10.53 per cent on the day, trading at C$0.315 per share at 2:45 pm ET

BioHarvest Sciences (BHSC) has closed the second tranche of its oversubscribed private placement of convertible notes.

The company expects the offering to close an additional tranche of up to $3 million by December 15, 2022.

Under the second tranche, the company has issued notes in the principal amount of $2,612,742.28. With the closing of this tranche, the total amount raised under the offering to date is $ 9,490,985.94.

All securities issued are subject to a four-month statutory hold period, expiring March 16, 2023.

Vancouver-based BioHarvest Sciences Inc. (BHSC) is the developer and exclusive owner of proprietary and patent-protected BioFarming technology.

BioHarvest Sciences Inc. (BHSC) is up 10.53 per cent on the day, trading at C$0.315 per share at 2:45 pm ET.


More From The Market Online

Tilray’s Breckenridge Brewery honours Denver Nuggets with new ale

Tilray Brands (TSX:TLRY) subsidiary Breckenridge Brewery launches a new ale to recognize the 2023 NBA championship-winning Denver Nuggets.

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Organigram looks to raise capital as cannabis stocks surge

Organigram (TSX:OGI), one of Canada's first cannabis stocks, announces an overnight marketed public offering of units for up to C$25 million.